Huadong Medicine Balance Sheet Health
Financial Health criteria checks 6/6
Huadong Medicine has a total shareholder equity of CN¥24.6B and total debt of CN¥2.6B, which brings its debt-to-equity ratio to 10.5%. Its total assets and total liabilities are CN¥39.4B and CN¥14.9B respectively. Huadong Medicine's EBIT is CN¥4.4B making its interest coverage ratio -574.9. It has cash and short-term investments of CN¥3.7B.
Key information
10.50%
Debt to equity ratio
CN¥2.58b
Debt
| Interest coverage ratio | -574.9x |
| Cash | CN¥3.71b |
| Equity | CN¥24.56b |
| Total liabilities | CN¥14.88b |
| Total assets | CN¥39.45b |
Recent financial health updates
We Think Huadong Medicine (SZSE:000963) Can Stay On Top Of Its Debt
Nov 29
Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly
Jun 28Recent updates
Huadong Medicine Co., Ltd's (SZSE:000963) Intrinsic Value Is Potentially 77% Above Its Share Price
Apr 02Take Care Before Diving Into The Deep End On Huadong Medicine Co., Ltd (SZSE:000963)
Feb 28Be Wary Of Huadong Medicine (SZSE:000963) And Its Returns On Capital
Feb 12An Intrinsic Calculation For Huadong Medicine Co., Ltd (SZSE:000963) Suggests It's 49% Undervalued
Dec 16We Think Huadong Medicine (SZSE:000963) Can Stay On Top Of Its Debt
Nov 29Investors Aren't Buying Huadong Medicine Co., Ltd's (SZSE:000963) Earnings
Nov 13There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital
Sep 23Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price
Aug 05Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly
Jun 28There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital
Jun 10Financial Position Analysis
Short Term Liabilities: 000963's short term assets (CN¥22.4B) exceed its short term liabilities (CN¥14.4B).
Long Term Liabilities: 000963's short term assets (CN¥22.4B) exceed its long term liabilities (CN¥533.1M).
Debt to Equity History and Analysis
Debt Level: 000963 has more cash than its total debt.
Reducing Debt: 000963's debt to equity ratio has reduced from 13.3% to 10.5% over the past 5 years.
Debt Coverage: 000963's debt is well covered by operating cash flow (131.9%).
Interest Coverage: 000963 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 15:07 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Huadong Medicine Co., Ltd is covered by 36 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Changming He | BOCI Research Ltd. |
| Ethan Cui | BofA Global Research |
| Shuchang Liu | Changjiang Securities Co. LTD. |